Agoracom Blog Home

Posts Tagged ‘#Cannabinoids’

« Older Entries

Mountain ValleyMD $MVMD $MVMDF Enters LOI To Develop Products for the Medical Sleep Market Strictly Using Cannabinoids $CTLT $MRNA $NVA $RWB

Posted by AGORACOM at 4:55 PM on Thursday, September 30th, 2021
This image has an empty alt attribute; its file name is MVMD-square-1.jpg

MVMD Takes Existing Vaccines and Drugs – And Delivers Them Better. Both Into The Body and By Transportation To The World. Way Better.

For the purposes of introducing you to Mountain Valley MD (MVMD), we’ll use vaccines as an example given the state of the world since COVID-19 arrived. Specifically, we’ve all heard more about vaccines in 12 months than we have in the last 12 years. One thing we all know about vaccines is that vaccination is the safest way to protect people against infectious diseases.

BUT

One thing we don’t know or understand about vaccinations is that they are only as good as:

1. The global physical delivery system that actually gets them from the manufacturer to the hands of nurse who injects the vaccine;

2. The delivery system into your body (i.e. injection)

If either parts of these delivery systems are weak, or even fail, a vaccine loses some or even all of its potency – and that’s not good. This is where MVMD comes in. They don’t make the vaccines, drugs or pharmaceuticals.

What they do is make their delivery better. Their physical delivery until their ultimate delivery into your body – and that is very good. By doing so, they help save lives and they help manufacturers be more profitable – and that is very good for humanity and shareholders.

A “magic bullet” is of little use without a “magic gun” – Mountain Valley MD Is The Magic Gun.

Check out these Trials & Research MVMD is accomplishing with their Vaccine technology to improve our lives:

* Expanding Oncology Work for BreastCancer using Quicksol™ technology applications

* Farm Animal Trials Using Solubilized Ivermectin

* Discovering Immediate Demand for Generic Ivermectin Uses

The latest news Involves utilizing their vaccine technology to address & develop products for the Medical Sleep Market in the U.S. strictly using cannibinoids.

Sit back and enjoy the great interview with President & CEO Dennis Hancock as he explains the developing relationship with Red White & Bloom to create products for the US sleep market.

Tags: , , , , ,
Posted in All Recent Posts, Beyond The Press Release, Mountain Valley MD | Comments Off on Mountain ValleyMD $MVMD $MVMDF Enters LOI To Develop Products for the Medical Sleep Market Strictly Using Cannabinoids $CTLT $MRNA $NVA $RWB

Applied BioSciences $APPB: Innovative CBD System Balancing $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 2:31 PM on Monday, January 27th, 2020

SPONSOR: Applied BioSciences is a vertically integrated company focused on the development and commercialization of novel, science-driven, synthetic cannabinoid therapeutics / biopharmaceuticals; targeting the endocannabinoid system to treat a wide-range of diseases across multiple therapeutic areas. Click Here for More Info

https://cdn.chiroeco.com/wp-content/uploads/2020/01/i1-20-digital4-1024x576.jpg
An endocannabinoid deficiency can result in a host of patient afflictions, but this innovative CBD balancing strategy can help patients

All cannabidiol (CBD) is not created equal in clinical practice in terms of implementation. The most frustrating thing for clinicians and also for patients is when an intended protocol doesn’t work. As I discuss later under the “With treatment, start low” section of this article, there are ways to use CBD most effectively.

You probably weren’t taught this in medical school, but CBD works on the endocannabinoid system (ECS). The ECS contains CB1 and CB2 receptors, in addition to other receptors that are activated by the naturally occurring endocannabinoids made in our bodies, called anandamide and 2-AG. We all have CB1 or CB2 receptors within our body — if you have a cat or dog, they have these receptors too. All mammals do. How could it be that we did not even know of the predominance of the ECS until 1992?

What the endocannabinoid system can do

Patients coming in worn out can be a sign of endocannabinoid deficiency and the inability to support their pathways optimally, much like adrenal fatigue. Phytocannabinoids like CBD obtained from hemp products can act on the same receptors as endocannabinoids made in the body. CBD receptors, much like opioid receptors, control pain, but via a different mechanism.

Patients arrive at our clinical practices fatigued, anxious, in pain, inflamed, and lots reach a point of adrenal burnout, adrenal fatigue. Indeed, that is often the case because they are suffering from an endocannabinoid deficiency. We see people who have low adrenal function at noon, and in the evening, they are tired, dragging, eat lunch, get a little spike, and then they start free falling again. They’re flat-lining. How is it that we wake up each morning anticipating with trepidation and run with go, go, go pace and finish the day glad to have survived another day? Life is meant for more than that; it is time to shift our goals from merely surviving to thriving mode!

Researchers observed approximately six years ago that people were more anxious and depressed in the middle of the summer than ever before, a new phenomenon. This goes against what we previously believed, that depression spiked mostly in the holiday season and Thanksgiving and after the winter solstice. But now we’re seeing people are worn out even in summer. Indeed, the endocannabinoid system plays a role here.

Anandamide is one of our endocannabinoids. When it becomes lower, patients are more anxious. There is less healing of the brain, less neurogenesis, and the hypothalamic-pituitary axis is triggered, causing a whole cascade of events to occur. What we now know is that the endocannabinoid system naturally, or with the use of CBD, alters our microbiome in our gut, beneficially affecting the gut-brain axis. The GI tract is the site of many receptors. We make about 70% of our serotonin, the happy-brain chemical, in the GI tract. About 70-80% of our immune system is in our GI tract, so is it any surprise that we have CB1, CB2 regulatory pathways in our GI tract that work via the endocannabinoid system to control inflammation? These same pathways can be regulated using an innovative CBD strategy.

Migraines and the endocannabinoid system

With endocannabinoid deficiency symptoms patients can get migraines. We thought migraines were just triggered by tyramine-rich foods, such as cheese, fermented foods, and salami and other such foods; along with other triggers as well.

However, the endocannabinoid pathway is designed to control pain and inflammation and also regulate the immune system to a large degree. I have found in my clinical practice that innovative CBD strategies can be useful in supporting the health of migraine sufferers.

Treat the brain, treat the pain

The body is designed with innate intelligence to sustain optimal performance. People ask, “Well, how is CBD metabolized?” It’s primarily metabolized through the liver, and as a result, it goes through the cytochrome 450 and other pathways.
Wellness is ultimately about homeostasis. We all know the term entropy, the tendency for the universe to move toward chaos. But our body exerts a phenomenal amount of energy to maintain order and wellness. However, if the endocannabinoid system becomes deficient, this will adversely affect wellness. This endocannabinoid deficiency, in turn, affects the microbiome, contributing to a less healthy endocannabinoidome.

CBD can conserve anandamide that is made by the body, and CBD can support anandamide conservation in an attempt to bring the body back into homeostasis. The endocannabinoid system supports brain health. By treating the brain, it addresses the pain, because if we didn’t have a brain, we wouldn’t feel the pain from a perception perspective.

Anxiety also is a biochemical process. It’s real. A lot of people say, “It’s all in my head.” No, stress is real because it’s a physiological effect. There is biochemistry involved in anxiety. We want to use innovative CBD strategies to support calming pathways and bring peace and harmony into the brain.

Endocannabinoid deficiency issues

If a patient has brain inflammation, neuroplasticity is not going to be as healthy or robust. And the fact is, on a typical day, we lose about 86,400 brain cells. CBD is an anti-inflammatory application. And from a neuropathic perspective, activation of cannabinoid receptors is essential. I’ve looked at research involving the endocannabinoid system relative to cancer medications and so forth. Not being an oncologist, I am not suggesting this is a treatment for cancer, but there are pain, stress and immune challenges that often need to be associated with this disease state, so visiting with one’s provider in this arena is vital.

We can start manifesting symptoms of migraines, fatigue, irritable bowel, whatever it might be, as a result of being subpar, insufficient or deficient of endocannabinoids. An endocannabinoid deficiency manifests itself as simply that the body has gotten worn down, much like low adrenal function, often called adrenal fatigue. So we need to support that pathway to bring it back on track like we would any other functional biochemistry, which our body is designed to do. And since we’re designed to make endocannabinoids, we need to bring those levels back up to par.

With treatment, start low

The goal is to start low and go slow, as a little bit can go a long way for many patients. More is not always better, as each person responds differently based on genetics, biochemistry and individual need.

Just like if you’re performing an adjustment, a little bit of a movement might get the job done. Work with gentle modulation of the endocannabinoid system. You’re working within the innate ability of the body.

Fifteen to 25 milligrams per day is what I start my patients on. In a week or two, if I need to move them up to 25 mg two to three times a day, I will. Once again, if a little bit gets the job done, why more? It is of paramount importance to respect the innate delicate balance physiology of the body. Some patients will need much higher doses because of their endocannabinoid insufficiency or potential genetic polymorphisms. You’re going to encounter genetic polymorphisms, or what I termed mutations of the CBD receptors and the CBD pathway.

I never go to high-milligram doses, especially on patients taking pharmaceutical drugs, without working with their pharmacists, because CBD can affect similar liver detoxification, as well as other biochemical pathways of how drugs are metabolized, much like grapefruit juice, can impact many of the same medications. We want to also support those drug-metabolizing pathways with diet and lifestyle.

CBD, when dosed properly, can positively supplement a health-promoting diet and lifestyle. It’s not a substitute for these things. So, we want to ensure we’re taking steps to support the body at a foundational level. Additionally, we always want to ensure the THC levels in the CBD you are using are less than 0.3%, or that the CBD contains no THC, when targeting hemp-derived CBD.

We all get broken or get older

Endocannabinoid deficiency is associated with low cortisol, stress and adrenal fatigue. We’re all getting older. Our mitochondria are wearing down. Our nitric oxide levels aren’t as robust as they used to be, and we need support at a fundamental level. In regards to the 65 potential molecular targets that are currently known for CBD, there is a lot of untapped potential here relative to stress and aging. Innovative CBD use is a new area; it can be a scary area, but remember, our bodies have been producing endocannabinoids for millennia. All we’re doing is supporting a natural pathway.

source: https://www.chiroeco.com/innovative-cbd/

Tags: , , , , , , , , , ,
Posted in All Recent Posts, Applied BioSciences | Comments Off on Applied BioSciences $APPB: Innovative CBD System Balancing $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Applied BioSciences $APPB: How CBD and The Endocannabinoid System Work Together $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 10:43 AM on Tuesday, January 21st, 2020

SPONSOR: Applied BioSciences is a vertically integrated company focused on the development and commercialization of novel, science-driven, synthetic cannabinoid therapeutics / biopharmaceuticals; targeting the endocannabinoid system to treat a wide-range of diseases across multiple therapeutic areas. Click Here for More Info

Before we can take a look at how CBD and the Endocannabinoid System (ECS) work together, we must first understand the ECS.

The human body has an endocannabinoid system, just like it has an endocrine system and a number of other systems that work together to function. The ECS is what makes it possible for CBD, THC, and other cannabinoids in the marijuana and hemp plants – there are hundreds – to work on the body.

In 1988, researchers found the first cannabinoid receptor in the brain of a rat. They found that the receptors interacted exclusively with receptors found in the cannabis compound, THC. That’s the cannabinoid everyone’s most familiar with because it is the compound responsible for the stoned feeling associated with marijuana consumption.

The researchers discovered that the receptors were concentrated in areas of the brain that plays a role in a number of physiological and mental processes, including emotion, motor coordination, high cognition, and memory.

In 1993, another cannabinoid receptor was discovered. It was found distributed throughout the immune system and peripheral body tissues. It displayed the same reaction to THC as the first receptor.

In 1995, the two receptors, that had been named CB1 and CB2, were found not only in rats, but in humans, and thousands of other species.

As technology advanced, researchers further explored the relationship between cannabinoid receptors in the body, known as endocannabinoids, and the cannabinoid receptors in cannabis compounds such as CBD oil and THC – known as phytocannabinoids.

What is the Purpose of Endocannabinoids?

The endocannabinoid system was discovered in the late 1990s, and since then, researchers have learned a great deal about the relationship between phytocannabinoids and endocannabinoids.

Because we know endocannabinoids are present throughout the body in numerous functions, researchers believe they may help maintain these functions.

Imagine for a moment the body is a machine, where each system works together to keep the machine moving and working. The immune system, for instance, would be the filtration system. The brain would be the motherboard, and the endocannabinoids help to maintain the systems.

CB1 receptors are concentrated in the brain and central nervous system. Your central nervous system is responsible for maintaining all the core functions such as pain perception, stress response, motor activity, and memory.

CB receptors are located in many of the peripheral organs in the body, suggesting they are core components of the cardiovascular system, the immune system, and the muscular system.

Why Phytocannabinoids Matter

Machines, whether due to natural aging, poor maintenance, or damage, may malfunction. And like those machines, our body’s systems and parts can break down and malfunction, causing issues within the entire body and any number of health conditions.

Endocannabinoids help maintains your body’s health, but if the level of endocannabinoids in the body declines, in theory, they’d only be able to maintain the body’s current state of health. As such, there likely wouldn’t be enough to stop it from declining any further. Over time, the health level decreases gradually, and in the process, creates bigger health problems.

That’s where phytocannabinoids, such as CBD come into play.

How CBD Works in the Body

Research has taught us that when CBD bonds with either the CB1 or CB2 receptors in the body, it either alters or improves that receptor’s capabilities, which improves that receptor’s functionality.

If the body is suffering a cannabinoid deficiency, adding them to your body, for example, by using CBD gummies for stress, helps to equalize the deficiency. Right now, studies point to the theory that cannabinoids are a finite resource. The deficiency of cannabinoids may cause a number of health issues, including irritability and headaches.

Essentially, using CBD enables us to boost our ECS. Because it bonds with our CB1 and CBD2 receptors, CBD helps the body maintain vital health functions and helps restore balance, also known as homeostasis, within the body. This is the reason it has so many health benefits.

CBD Benefits

When you really think about it, the majority of health problems can be traced back to an imbalance somewhere in the body.

In a healthy body, all is as it should be, and the body is balanced. In an unhealthy body, however, there is either too much or too little of something (or multiple somethings). This creates a disruption in homeostasis and presents a variety of symptoms, which vary depending on the nature of the imbalance.

Think about the various health conditions that are a result of imbalance, and how CBD can help improve these conditions by restoring balance:

  • Inflammation: This is often characterized by a part of your body swelling, and sometimes becoming hot. It can be incredibly painful, and range from mild, to severe enough to incapacitate someone. Inflammation in the body is linked to autoimmune disorders, arthritis, and bacterial infections. CBD can be helpful to treat inflammation because it suppresses the inflammatory pathways and responses, stimulates regulatory cell production, and manages our pain perception.
  • Seizures: Seizures are the result of erratic electrical impulses in the brain, which causes violent shaking in the body. In patients suffering from two severe forms of epilepsy known as Lennox Gaustat Syndrome and Dravet Syndrome, CBD reduces the number of seizures because it slows down the excitatory nerve activity and subdues the brain’s reaction to the intense signals that cause the overload.
  • Anxiety and stress: Most people experience stress and anxiety as a response to situations that are perceived as unwanted, dangerous, or risky. Hormonal imbalance or excessive messages in the brain boosts cortisol levels and causes you to feel stress. CBD combats this by regulating how your brain responds to stress signals and maintaining normal cortisol levels.

These, of course, are only a few examples of the studies supporting CBD as an effective treatment.

There are hundreds of other studies supporting its use to treat a wide number of other conditions, such as addiction, acne, depression, schizophrenia and more. It’s all because of our ECS, and the fact that our bodies contain parts linked directly to the cannabis plant is pretty amazing.

SOURCE: https://www.latintimes.com/how-cbd-and-endocannabinoid-system-work-together-454648

Tags: , , , , , , , , , , ,
Posted in All Recent Posts, Applied BioSciences | Comments Off on Applied BioSciences $APPB: How CBD and The Endocannabinoid System Work Together $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Applied BioSciences $APPB: CBD vs THC – Full Spectrum, Broad Spectrum and Pure Isolate 2020 Comparison Guide $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 2:34 PM on Tuesday, January 14th, 2020

SPONSOR: Applied BioSciences is a vertically integrated company focused on the development and commercialization of novel, science-driven, synthetic cannabinoid therapeutics / biopharmaceuticals; targeting the endocannabinoid system to treat a wide-range of diseases across multiple therapeutic areas. Click Here for More Info

A properly updated 2020 guide on CBD versus THC along with a complete review of the entourage effect differences and health benefits of using a full spectrum, broad spectrum or pure isolate CBD-infused product.

HealthMJ is actively mapping out the entire CBD ecosystem, from the best CBD oils, gummies, skincare, salves/balms, drinks/beverages and pet products – we got you covered; and one of the most popular questions we receive from our attentive audience is how CBD vs THC works; more specifically the differences between full spectrum CBD, broad spectrum CBD and pure isolates.

As the rapidly shifting landscape of medicinal cannabis continues to unfold in 2020, hemp and marijuana plants are both spectacles to watch in their own right given the prominent cannabinoid community of compounds, namely in THC and its cousin phytocannabinoid CBD.

With all of the new information coming out about CBD and its potential health benefits, it’s only fair that you might question how CBD compares to marijuana or THC-infused products and so forth. Many individuals continue to be concerned about CBD, and while there are many risks and dangerous concerns to address, research says maybe you should consider the options to get ahead of the curve and know the variations best available for you.

When it comes to terms like CBD, THC, full-spectrum, broad-spectrum, and isolates; it’s hard to know and fully understand what these terms mean and just what the differences are between them or how they compare to one another. But our CBD vs THC guide is designed to do just that; remove the clutter, simplify the terminology and showcase each advantage they all have independently as well as talk about the ‘entourage effect’.

The thing is, there is a lot of varying CBD and THC-infused product information available, and it is so very important to educate yourself before passing any judgment on these products. Making an effort to be in the know will not only increase your knowledge base but just might present you with life-changing information given your occupation, bodily needs or desired medicinal effects.

Understanding that “knowledge is power,” we put together a guide the will detail each of these items in turn (CBD, THC, full-spectrum, broad-spectrum, and isolates) as well as compare them and explain to you how each of these factors might relate to the other.

We will share with you various statistics, studies, definitions, and a ton of valuable information for each subject. To begin, we will break down each subject separately, and then we will come back and tie some information together for your reference.

We hope you will tune into this CBD and THC overview breakdown and the valuable information presented within our cannabis oil-infused product guide for buying the best full-spectrum, broad-spectrum or pure isolate option for you.

CBD: All the Rage, None of the High

CBD products have taken the world by storm. While it has quickly become the most popular best-selling herbal extract in the health and wellness industry last year, many are still on the fence whether or not to use a CBD-infused supplement. Have you tried them yet? Are you scared to take that step and open the door to the possibilities of what CBD can provide for you? CBD products were initially quite controversial as they are instantly associated with marijuana.

The truth is, CBD really is not comparable to marijuana and, in fact, many times contains no THC (which is the property that typically enacts psychoactive responses in use of marijuana) or a minuscule percentage.

Additionally, CBD products are heavily regulated as to how much THC can legally be in them for over-the-counter distribution. It is no secret by now CBD has become a go-to option for many men and women looking for a natural and potentially reliable solution for issues such as pain relief, anxiety, irritation, and the like. Before choosing a CBD product, it is important to understand the difference between the three of the most common-types of formulas, which are full-spectrum (with THC), broad-spectrum (no-THC) and isolate (pure CBD). Fortunately, this post is here to help.

Are you curious yet? Let’s dive a bit deeper.

What Exactly is CBD?

CBD is short for cannabidiol. This cannabidiol is otherwise known as a phytocannabinoid. These cannabinoids come directly from the cannabis plant. Cannabis plants contain more than 100 cannabinoids in them.

When minerals are extracted from the cannabis plant, CBD accounts for approximately 40% of the extracts, which results in CBD being readily available for processing. CBD can be obtained from hemp without THC in the extraction.

What does that mean? THC is the property that often gives cannabis a bad name. It is THC that produces the “high” that is associated with some cannabis usage, particularly smoking cannabis. However, you should know that THC is either extremely limited or completely non-existent in CBD when it is produced.

In fact, many manufacturers of CBD products extract the cannabidiol with an extreme process specifically for the purpose of delivering a pure product and reducing THC levels. In this manner, the CBD then does not make you high and formats to legal regulations as well.

The Benefits of CBD

Studies have shown that CBD products can produce a significant number of health benefits, many of which you may not have ever been aware of. Research has been increasing, but there is also still a lot to learn about CBD.

There are many benefits that have been discovered through studies and trials thus far. Here are a few of the most common and well-known benefits of CBD products:

  • Pain Relief
  • Anti-inflammatory properties
  • Anxiety relief
  • Cancer treatment and relief
  • Epilepsy and seizure disorder treatments
  • Alzheimer’s treatment
  • Migraine relief
  • Fight acne
  • Fights neurological symptoms and disorders

You might be able to pick out a few of the items on this list that have been primarily untreatable with everyday medication. When there is medication available, it can have extensive side effects.

But consider a safe and legal treatment to things like cancer, epilepsy, and Alzheimer’s – amongst other hard to treat diagnoses. Does this mean CBD will help your body heal from these disorders, or will it simply help relieve the symptoms?

Research and studies are still new and not fully conclusive. It is hard to say whether CBD could essentially eliminate any of the disorders listed, but if it can help fight or treat the associated symptoms, it is certainly worth consideration.

To give you an idea of how CBD works with these various disorders, let’s break a few of them down further.

CBD and Alzheimer’s Treatment

Alzheimer’s has long been a disorder that is primarily untreatable. Of course, there is medication to help those with Alzheimer’s, but it does little by way of reducing symptoms or slowing the process of the disease.

Alzheimer’s is primarily a brain disorder that progresses rather slowly at most times. It can move quickly though in some people. Alzheimer’s causes the victim to lost memories, history, and even the memory of how to complete specific skills necessary to care for themselves.

As Alzheimer’s progresses, many people revert to old memories and don’t know the people closest to them when they see them. They forgot how to do basic tasks and ultimately become unable to care for themselves safely.

All of these effects of Alzheimer’s are functionally related to the brain suffering from inflammation. This inflammation often causes excessive oxygen to build-up, which in turn leads to the effects we are familiar with as Alzheimer’s. The brain cells become blocked and therefore decline.

In comes CBD products, recent studies show that CBD can reduce this inflammation, allowing that oxygen that has built up due to brain cell blockage to seep out and therefore decreasing many Alzheimer’s symptoms.

This systematic process from CBD acts as an antioxidant for the brain cells by reducing or eliminating the inflammation that causes blockage and therefore causes the disease to take full form. With this relief, the effects of Alzheimer’s are greatly reduced and slowed.

This is not to say CBD cures Alzheimer’s but rather that it can reduce the process and provide relief of many of the symptoms, straight from the root cause.

CBD and Epilepsy Treatment

Epilepsy and other seizure disorders have been studied for health benefits related to CBD treatment. Epilepsy is another neurological disorder in which the sensory processes in your brain are triggered, which then leads to seizures.

Epilepsy has been challenging to treat through the years and at times, is left untreated. There are medications available, but there is no guarantee they will work. They may reduce seizures or the intensity of seizures, but the results vary on individuals, and, of course, the results are only as good as the medicine available.

CBD, also, may not be effective for every user. However, it has been found in studies to dramatically reduce the number of seizures as well as the length of seizures in those affected by the disease.

In 2018, the FDA approved Epidiolex to be used for epilepsy treatment in certain situations. There are two forms of epilepsy it has been approved to treat and an age requirement as well. Epidiolex is a formula of CBD that is purely plant-based but has been studied and researched for its effectiveness in regards to epilepsy treatment.

CBD Pain & Anti-Inflammatory Relief

For a number of years, chronic pain has been treated with pain relievers. Pain relievers that can cause dependency and addiction for the user and often produce side effects that far outweigh the relief of the pain.

Not only can pain relievers lead to addiction but essentially, they can become ineffective because of the dependence effect they tend to have on the user. This is an unfortunate effect for those who are simply seeking relief.

We’ve grouped Pain relief and anti-inflammatory properties together here because they are often related. Chronic pain is typically directly related to inflammation, as are various diseases and disorders that lead to common pain, fibromyalgia, sclerosis, lupus, etc.

Research is still quite limited on CBD’s abilities to reduce pain or inflammation, and therefore, there is no FDA seal of approval yet, but that doesn’t mean there isn’t information available for review.

It is believed through current studies that CBD directly communicates to your ECS or endocannabinoid system. This system signals cells to emit pain signals to your body when an area is damaged. CBD interacts with ECS to improve the quality of these signals, relieving the feelings of pain or inflammation within your body.

CBD and Anxiety Relief

Anxiety has become one of the fastest rising disorders. Anxiety continues to become a common diagnosis, but it shouldn’t be. In this frantic world that is constantly changing and evolving, anxiety is the last thing we should be worried about, and clearly, it is all about “worry.”

Again, research is just beginning, and the results are currently limited. The results of these studies continue to be tested, but for now, we work with what limited information we have available. Studies are showing that CBD can dramatically reduce anxiety and the effects of anxiety.

How does that work? CBD enhances calming properties through the brain. CBD somehow is able to bind to those brain receptors that trigger the anxiety response from your brain, and therefore, your anxiety is reduced, and you remain calmer and more reasonable rather than anxious and concerned.

Do You See a Connection?

Many of the disorders and symptoms you see above have something in common, they are triggered by cells or brain receptors that essentially lead to the disease or disorder. CBD appears to work quite well with disorders that essentially start with brain function.

Studies are still limited and are still taking place. Results are varied, and there is not yet enough evidence to truly rely on CBD, but there are positive results and signs thus far. While many of the disorders we specifically discussed are brain-related, CBD can have positive effects on other ailments as well.

The Legalities of CBD

CBD-infused product supplementation was the number one most trending ingredient in 2019. They have become more pronounced and popular in recent years as people discover just what CBD can offer for health benefits. There are a number of benefits and things still being discovered about CBD and what it has to offer.

It seems like everywhere you go, you can find CBD products from oils, gummies, sprays, and lotions to even CBD pet products. But is it really legal? How do you know it won’t cause you legal issues in the end?

Cannabis is certainly not new, but it still has limited legality for sales, use, and distribution. It cannot be openly sold in many states. Only a few states have passed bills allowing recreational or medicinal use of marijuana in a legal capacity.

However, in 2018, the Farm Bill was passed/updated, and restrictions on CBD specifically were removed from various legal restrictions if the CBD is extracted from a hemp plant. It is now legal to produce, buy, and sell CBD products IF they contain less than .3% THC.

The primary statement here is the products must fall into the guidelines of following the THC level guidelines. Many CBD companies simply meet the minimum guidelines while others take it even farther and purify their CBD or even produce a formula with 0% THC.

SOURCE: https://www.healthmj.com/cbd/thc-full-spectrum-broad-spectrum-isolate/

Tags: , , , , , , , , , ,
Posted in All Recent Posts | Comments Off on Applied BioSciences $APPB: CBD vs THC – Full Spectrum, Broad Spectrum and Pure Isolate 2020 Comparison Guide $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Terpenoids And Cannabinoids – What’s The Difference? SPONSOR: Applied BioSciences $APPB $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 12:00 PM on Monday, January 6th, 2020

SPONSOR: Applied BioSciences is a vertically integrated company focused on the development and commercialization of novel, science-driven, synthetic cannabinoid therapeutics / biopharmaceuticals that target the endocannabinoid system to treat a wide-range of diseases across multiple therapeutic areas Click Here for More Info

If you have been studying cannabis products in depth to find out that one full-spectrum CBD oil that would suit all your needs then you’d have come across the word terpenes. But what are these terpenes, or as others refer them, terpenoids?

Of course, if you are looking to buy CBD, you would be aware of what cannabinoids are. these are compounds found in the cannabis plants, hemp and marijuana. So now you have two terms cannabinoids and terpenoids – but what’s the difference between the two? let’s take a look at this below:

Cannabinoids

Cannabinoids like cannabidiol and tetrahydrocannabinol have therapeutic properties. They interact with the natural endocannabinoid system in your body. What they basically do is that they control the functionality of cells – this means they manage cell signaling.

Cannabinoids regulate the receiving, processing, and sending of messages between cells. A cannabinoid like CBD can interact with cannabinoid receptors in the ECS and regulate your mood, anxiety, inflammatory response, and much more.

While THC and CBD are the most popular cannabinoids that have studies supporting their effects, there are hundreds of other cannabinoids too. These include CBG and CBN among others. All cannabinoids come with distinct features.

Terpenes

Terpenes or terpenoids are aromatic molecules not only found in cannabis but in several other plants as well. These as well have therapeutic properties. They are found in fruits as well. Terpenes in the lavender flower are responsible for its unique aroma and soothing properties.

Terpenes also found in citrus fruits and berries too. One terpene that exists in both cannabis as well as a fruit, mango, is myrcene. The aroma of weed that many people appreciate comes from this very terpene. Inside plants, terpenes play a very important role. They protect against the attack of pests, bacteria and other external agents. The amount and type of terpenes in cannabis plants varies from one strain to another.

The Entourage Effect

Experts recommend you to go for a full-spectrum CBD formula because it contains cannabinoids as well as terpenes. Cannabinoids and terpenoids work together to provide better benefits. They have an entourage effect together which enables you to get better result sooner. This is because like cannabinoids, terpenes also have health profiting qualities.

For instance, some terpenes have an anti-inflammatory nature while others are great for stress relief. As you may already be aware, CBD also provides these benefits. Of course, when in combination with other compounds that have similar properties benefits that you drive are more.

Verdict

Cannabinoids and terpenes are compounds found in the cannabis plant. Both have therapeutic properties but are different. Terpenes are aromatic molecules responsible for the flavor of a plant and fragrance. Cannabinoids interact with the ECS of the body. Together they work even better which is why full-spectrum CBD is revered more than CBD isolate.

SOURCE: https://prospercbdnews.com/Terpenoids+And+Cannabinoids+-+What%E2%80%99s+The+Difference%3F

Tags: , , , , , , , , , , , , ,
Posted in All Recent Posts, Applied BioSciences | Comments Off on Terpenoids And Cannabinoids – What’s The Difference? SPONSOR: Applied BioSciences $APPB $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Applied BioSciences $APPB Subsidiary, Trace Analytics, Receives Extension of Contract of Services from Washington State Department of Agriculture $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 8:37 AM on Wednesday, December 18th, 2019
  • Trace Analytics Inc. is a leading scalable analytics cannabis/cannabinoid laboratory poised to meet the demands for mandated regulatory cannabis/cannabinoid testing
  • WSDA contracted Trace Analytics for the purpose of doing cannabinoid profiling for the State’s industrial hemp program to ensure the percentages of certain cannabinoids are below Federal limits

Applied BioSciences Corp. (OTCQB:APPB) (“Applied” or the “Company”), today announced that the Washington State Department of Agriculture (WSDA) has extended its contract for services with Applied’s majority owned subsidiary, Trace Analytics Inc. (“Trace”).

The WSDA contracted Trace beginning in July 2019 for the testing of Industrial Hemp samples and percentage testing for delta 9-tetrahydrocannabidiol (THC) and delta 9-tetrahydocannabinolic acid (THC-A) to ensure the percentages of certain cannabinoids are below Federal limits.

“We are grateful for our relationship with the WSDA and are pleased to continue cannabinoid profiling for the WSDA’s Industrial Hemp program. The testing and reporting of results that we have conducted to date have demonstrated the quality of our analytics and our dedication to ensuring compliance with Federal limits,” stated Jason Zitzer, Chief Operating Officer of Trace Analytics. “We provide expert consulting services to government entities at all levels around the world and are appreciative to WSDA to have been selected as the sole lab to conduct their testing. This contract extension provides another opportunity toward establishing a higher quality for cannabis and hemp testing.”

Trace Analytics Inc. is a leading cannabis science and technology company with significant footprints in lab testing, research and development and licensing. Trace Analytics was started by a group of scientists who specialized in analytical chemistry, genetics and molecular biology, focused on ensuring compliance with public safety standards and end user safety. Trace Analytics is in the process of expanding throughout the United States, and globally with the goal of helping the rest of the world adopt “best practices” in cannabis and hemp testing. The Company also provides expert consulting services to legislators and regulators in many countries, states and municipalities around the world.

Based on Applied BioSciences’ stated strategic corporate shift to focus on its BioPharma division and the development and commercialization of novel therapeutics that target the endocannabinoid system (ECS), the Company is currently evaluating a strategic transaction of Trace Analytics. Applied is currently in late-stage discussions and expects to close the transaction by year end.

About Applied BioSciences Corp.

Applied BioSciences is a vertically integrated company focused on the development and commercialization of novel, science-driven, synthetic cannabinoid therapeutics / biopharmaceuticals that target the endocannabinoid system to treat a wide-range of diseases across multiple therapeutic areas. We also deliver high-quality consumer and OTC THC-free CBD products that promote overall health and wellbeing as well as state-of-the-art testing and analytics capabilities to our customers. For more information, visit appliedbiocorp.com and connect with the Company on Twitter, Facebook and LinkedIn.

Tags: , , , , , , , , , , ,
Posted in All Recent Posts, Applied BioSciences | Comments Off on Applied BioSciences $APPB Subsidiary, Trace Analytics, Receives Extension of Contract of Services from Washington State Department of Agriculture $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Applied BioSciences $APPB: What Is the Endocannabinoid System And What Is Its Role? $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 4:06 PM on Tuesday, December 17th, 2019

SPONSOR: Applied BioSciences is a vertically integrated company focused on the development and commercialization of novel, science-driven, synthetic cannabinoid therapeutics / biopharmaceuticals that target the endocannabinoid system to treat a wide-range of diseases across multiple therapeutic areas Click Here for More Info

Some of us consume cannabis for its mind-altering effects, while others seek symptom relief. But cannabis wouldn’t get us high or have some of its therapeutic benefits if our bodies didn’t already contain a biological system capable of interacting with its active chemical compounds, like THC.

Our endocannabinoid system does just that. But it isn’t there just to allow us to enjoy the effects of our favorite strain. It serves a vital purpose for our health and well-being because it regulates key aspects of our biology. So, what’s it doing, and how does it work?

Homeostasis: Staying in the Goldilocks zone

rocks on a beach

To understand the human endocannabinoid system, it’s helpful to know a little about one of the most fundamental concepts in biology: homeostasis. And the best way to understand homeostasis is to think of Goldilocks and the three bears.

That classic fairy tale illustrated the idea that the best outcome often lies somewhere in the middle, between two extremes. We don’t want things too hot or too cold, but just right.

Homeostasis is the concept that most biological systems are actively regulated to maintain conditions within a narrow range. Our body doesn’t want its temperature to be too hot or too cold, blood sugar levels too high or too low, and so on. Conditions need to be just right for our cells to maintain optimum performance, and exquisite mechanisms have evolved to draw them back to the Goldilocks zone if they move out. The body’s endocannabinoid system (ECS) is a vital molecular system for helping maintain homeostasis—it helps cells stay in their Goldilocks zone.

Key pieces of the endocannabinoid system (ECS)

Because of its crucial role in homeostasis, the ECS is widespread throughout the animal kingdom. Its key pieces evolved a long time ago, and the ECS can be found in all vertebrate species.

The three key components of the ECS are:

  • Cannabinoid receptors found on the surface of cells
  • Endocannabinoids, small molecules that activate cannabinoid receptors
  • Metabolic enzymes that break down endocannabinoids after they are used

Cannabinoid receptors

Cannabinoid receptors sit on the surface of cells and “listen” to conditions outside the cell. They transmit information about changing conditions to the inside of the cell, kick-starting the appropriate cellular response.

There are two major cannabinoid receptors: CB1 and CB2. These aren’t the only cannabinoid receptors, but they were the first ones discovered and remain the best-studied. CB1 receptors are one of the most abundant receptor types in the brain. These are the receptors that interact with THC to get people high. CB2 receptors are more abundant outside of the nervous system, in places like the immune system. However, both receptors can be found throughout the body (Figure 1).

endocannabinoid system cannabinoid receptors CB1 and CB2 in the body

Figure 1: Where are CB1 and CB2 receptors located in the body?
The CB1 and CB2 receptors are key players in the endocannabinoid system (ECS). They are located on the surface of many different types of cells in the body. Both receptors are found throughout the body, but CB1 receptors are more abundant in the central nervous system, including on neurons in the brain. In contrast, CB2 receptors are more abundant outside of the nervous system, including cells of the immune system.

Endocannabinoids

Endocannabinoids are molecules that, like the plant cannabinoid THC, bind to and activate cannabinoid receptors. However, unlike THC, endocannabinoids are produced naturally by cells in the human body (“endo” means “within,” as in within the body).

There are two major endocannabinoids: anandamide and 2-AG (Figure 2). These endocannabinoids are made from fat-like molecules within cell membranes, and are synthesized on-demand. This means that they get made and used exactly when they’re needed, rather than packaged and stored for later use like many other biological molecules.

Anandamide and 2-AG are the two major endocannabinoids produced naturally in the body

Figure 2: Anandamide and 2-AG are the two major endocannabinoids.
Cannabinoids are a class of molecules characterized by their ability to activate cannabinoid receptors like CB1 and CB2. Anandamide and 2-AG are the two major endocannabinoids produced naturally in the body. THC is the psychoactive plant cannabinoid produced by Cannabis. All three of these cannabinoids can activate the CB1 and CB2 receptors, although each one has a different potency at each receptor.

Metabolic enzymes

The third piece of the endocannabinoid triad includes the metabolic enzymes that quickly destroy endocannabinoids once they are used. The two big enzymes are FAAH, which breaks down anandamide, and MAGL, which breaks down 2-AG (Figure 3). These enzymes ensure that endocannabinoids get used when they’re needed, but not for longer than necessary. This distinguishes endocannabinoids from many other molecular signals in the body, such as hormones or classical neurotransmitters, which can persist for many seconds or minutes, or get packaged and stored for later use.

FAAH and MAGL are the key enzymes of the endocannabinoid system

Figure 3: FAAH and MAGL are the key enzymes of the endocannabinoid system.
Enzymes are molecules that accelerate chemical reactions in the body, often for breaking down molecules. FAAH and MAGL are key players in the ECS because they quickly break down endocannabinoids. FAAH breaks down anandamide, while MAGL breaks down 2-AG. These enzymes break down endocannabinoids very quickly, but are not effective at breaking down plant cannabinoids like THC.

The three key components of the ECS can be found within almost every major system of the body. When something brings a cell out of its Goldilocks zone, these three pillars of the ECS are often called upon to bring things back, thus maintaining homeostasis. Because of its role in helping bring things back to their physiological Goldilocks zone, the ECS is often engaged only when and where it’s needed. Dr. Vincenzo Di Marzo, Research Director at the Institute of Biomolecular Chemistry in Italy, put it to us this way:

“With the ‘pro-homeostatic action of the ECS’ we mean that this system of chemical signals gets temporarily activated following deviations from cellular homeostasis. When such deviations are non-physiological, the temporarily activated ECS attempts, in a space- and time-selective manner, to restore the previous physiological situation (homeostasis).”

In other words, the ECS helps bring things back to the biological Goldilocks zone.

Below we will consider examples of how the ECS helps maintain homeostasis in two areas: the firing of brain cells in the nervous system, and the inflammatory response of the immune system.

Endocannabinoid regulation of brain cell firing

Brain cells (neurons) communicate by sending electrochemical signals to each another. Each neuron must listen to its partners to decide whether it will fire off its own signal at any given moment. However, neurons don’t like to get too much input—there’s a Goldilocks zone. If they get overloaded by signals, it can be toxic. That’s where endocannabinoids come in.RelatedHow Does Cannabis Consumption Affect the Brain?

Consider a simplified scenario with one neuron listening to two others. One of these two neurons might become overactive and send too many signals to the neuron that’s listening. When that happens, the neuron that’s listening will make endocannabinoids specifically where it’s connected to the overactive neuron. Those endocannabinoids will travel back to the “loud” neuron where they bind to CB1 receptors, transmitting a signal that instructs it to quiet down. This brings things back to the Goldilocks zone, maintaining homeostasis (Figure 4).

endocannabinoid system regulation of brain cell firing

Figure 3: Endocannabinoid signals regulate how active our brain cells are.
Under normal circumstances (top-left), a given brain cell (neuron) will get just the right amount of input from its partners—not too much, not too little. However, some of its partners can become overactive, and send an excessive number of signals (top-right). The neuron that’s listening will detect this, and release endocannabinoids that tell the other neuron to quiet down (bottom). This kind of mechanism helps maintain homeostasis because it helps prevent neurons from sending out too many signals.

As the example above illustrates, endocannabinoids travel backwards, which is why they’re known as retrograde signals. Most of the time, information flow between neurons is strictly in one direction, from “sender” neurons that release neurotransmitter signals to “receiver” neurons that listen to those signals. Endocannabinoids allow receiver neurons to regulate how much input they’re getting, and they do this by sending retrograde signals (endocannabinoids) back to overactive sender neurons.

But the brain isn’t the only organ that needs to maintain homeostasis. Every other system of the body, from the digestive to the immune system, needs to carefully regulate how its cells are functioning. Proper regulation is crucial for ensuring survival.

Endocannabinoid regulation of inflammation

Inflammation is a natural protective reaction the immune system has in response to infection or physical damage. The purpose of inflammation is to remove pathogens (germs) or damaged tissue. The inflamed area is produced by fluid and immune cells moving into the area to do the dirty work and return things to their Goldilocks zone.

It’s important that inflammation be limited to the location of damage and doesn’t persist longer than needed, which can cause harm. Chronic inflammation and auto-immune diseases are examples of the immune system getting activated inappropriately. When that happens, the inflammatory response lasts too long (which results in chronic inflammation) or gets directed toward healthy cells (which is known as auto-immunity).RelatedCannabis and Arthritis

In general, endocannabinoids seem to suppress or limit the immune system’s inflammatory signals. Professor Prakash Nagarkatti, Vice President for Research at the University of South Carolina whose laboratory studies endocannabinoid regulation of immune responses, told us how tweaking the ECS might be a good way to treat inflammatory diseases.

“Most of our research demonstrates that endocannabinoids are produced upon activation of immune cells and may help regulate the immune response by acting as anti-inflammatory agents. Thus, interventions that manipulate the metabolism or production of endocannabinoids may serve as a novel treatment modality against a wide range of inflammatory disease.”

Consider a normal immune response triggered by a bacterial infection. First, immune cells detect the presence of bacteria and release pro-inflammatory molecules that tell other immune cells to come and join the fight. Endocannabinoids get released as well (Figure 4), which also signal to other immune cells for assistance and likely help limit the inflammatory response so it isn’t excessive. By tightly regulating inflammation, the immune system can destroy germs or remove damaged tissue, and then stop. This prevents excessive inflammation, allowing cells, and thus the body, to return to the Goldilocks zone.

the endocannabinoid system and inflammation

Figure 4: Endocannabinoids help regulate inflammation.
Under normal conditions (top-left), cells of the immune system patrol the body, on alert for any intruders, such as bacteria. During a bacterial infection (top-right), immune cells detect the presence of bacteria and then release a variety of molecules to help mount a defensive attack (bottom). These signals include pro-inflammatory molecules (small circles) that help recruit more immune cells to the site of infection. Endocannabinoids (small diamonds) also get released, and likely help regulate the magnitude and extent of this inflammatory response.

How do plant cannabinoids like THC and CBD interact with the endocannabinoid system?

The reason that plant cannabinoids have psychoactive and medicinal effects within the body is, in large part, because we have an endocannabinoid system (ECS) that they can interact with. For example, THC gets you high because it activates the CB1 receptor within the brain. Endocannabinoids like anandamide also activate CB1.

So why aren’t we constantly high?

A couple big reasons. First, THC doesn’t interact with CB1 receptors in exactly the same fashion as the body’s natural endocannabinoids. Second, the metabolic enzymes that quickly break down endocannabinoids like anandamide don’t work on THC, so THC lingers around for much longer.

It’s important to remember that molecules like cannabinoids and other neurotransmitters rarely interact with only one receptor type; they often interact with many. The plant-based cannabinoid CBD illustrates this nicely, as it interacts with numerous receptor types in the brain. So, while plant cannabinoids may activate the same cannabinoid receptors as endocannabinoids, they will likely interact with several other receptors and therefore have distinct effects.

CBD is also interesting because it can affect overall levels of endocannabinoids in the brain, referred to as “endocannabinoid tone.” CBD inhibits the FAAH enzyme, which breaks down anandamide. Thus, CBD can increase anandamide levels by preventing FAAH from breaking it down. Inhibiting the FAAH enzyme has been shown to be a useful strategy for treating anxiety disorders, and some of CBD’s anti-anxiety properties may come from its ability to inhibit this enzyme and thereby increase endocannabinoid tone.

Summary

The endocannabinoid system (ECS), comprised of cannabinoid receptors, endocannabinoid molecules, and their metabolic enzymes, is a crucial molecular system that the body uses to help maintain homeostasis. Because of its vital role in making sure that cells and systems remain in their physiological Goldilocks zone, the ECS is tightly regulated; it gets deployed exactly when and where it’s needed. However, this doesn’t mean that activating the ECS, through consumption of cannabis or by any other means, will always make things just right.

Like any other complex biological system, the ECS can go awry. “If deviation from physiological homeostasis is prolonged, due to either external factors or chronic pathological conditions, the eCS can lose its time- and space-selective mode of action and start affecting inappropriate cells,” Dr. Di Marzo explained. “In these cases, the ECS, instead of being beneficial, may actually contribute to disease progression.”

It’s important to remember that activating the ECS, through cannabis consumption or by any other means, isn’t a cure-all. Like most of biology, it’s complicated.

By understanding the biological Goldilocks principle (homeostasis), and how the ECS illustrates this at the cellular level, we can more deeply appreciate why we have an ECS to begin with, and how a variety of cannabis-based therapies might actually work. The presence and critical function of the ECS across many systems of the body, including the nervous and immune systems, explains why such a wide variety of ailments and disease states are responsive to cannabis-based interventions.

References
Gunduz-cinar O, Hill MN, Mcewen BS, Holmes A. Amygdala FAAH and anandamide: mediating protection and recovery from stress. Trends Pharmacol Sci. 2013;34(11):637-44. [PDF]
Ligresti A, De petrocellis L, Di marzo V. From Phytocannabinoids to Cannabinoid Receptors and Endocannabinoids: Pleiotropic Physiological and Pathological Roles Through Complex Pharmacology. Physiol Rev. 2016;96(4):1593-659. [PDF]
Nagarkatti P, Pandey R, Rieder SA, Hegde VL, Nagarkatti M. Cannabinoids as novel anti-inflammatory drugs. Future Med Chem. 2009;1(7):1333-49. [PDF]
Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol. 2008;153(2):199-215. [PDF]
Wilson RI, Nicoll RA. Endocannabinoid signaling in the brain. Science. 2002;296(5568):678-82. [PDF]
Zlebnik NE, Cheer JF. Beyond the CB1 Receptor: Is Cannabidiol the Answer for Disorders of Motivation? Annu Rev Neurosci. 2016;39:1-17. [PDF]

Tags: , , , , , , , , , , ,
Posted in All Recent Posts, American Creek Resources Ltd. | Comments Off on Applied BioSciences $APPB: What Is the Endocannabinoid System And What Is Its Role? $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Applied BioSciences $APPB: Announces Strategic Shift to Fully Focus on BioPharma Division $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 8:46 AM on Wednesday, December 4th, 2019
  • BioPharma division is focused on the development and commercialization of novel therapeutics that target the endocannabinoid system (ECS) –
  • BioPharma Division focus unlocks opportunities for non-dilutive capital to fund high-value pipeline –
  • Company seeking to spin-off Applied Products division comprised of a portfolio of consumer, animal health, women’s health and sports medicine CBD products –
  • Majority owned subsidiary, Trace Analytics, in late-stage discussions for a strategic transaction, expected close to year end 

Applied BioSciences Corp. (OTCQB:APPB) (“Applied” or the “Company”), today announced its strategic corporate shift to fully focus all initiatives and resources on its BioPharma division and the development of science-driven biopharmaceuticals that target the endocannabinoid system.

Through its Applied Products division, the Company currently develops multiple brands offering high quality health and wellness CBD products that conform to the highest regulatory standards and markets through established channels in the US. To date, the Applied Products business unit has seen robust year-over-year increase in top-line revenue. At this time and with the understanding that to be successful in the lucrative yet dynamic and very competitive consumer CBD space would require additional resources and capital allocations, the Applied Board has made the strategic decision to allocate all resources moving forward to the BioPharma business unit.

“After careful consideration, the Board has made the strategic decision that it is in the best interest of the Company and our shareholders, to spin off our consumer-facing CBD business, Applied Products. We believe that this streamlined corporate development pathway will unlock opportunities for non-dilutive capital to expand and advance our pipeline of novel therapeutics addressing areas of high value indications where there remain significant unmet needs,” commented Dr. Raymond Urbanski, Chief Executive Officer of Applied. “Both our Trace Analytics and Products business units represent promising investment opportunities and we are confident that we will be able to identify the right partners to give each unit the proper share of voice in this competitive field.”

“Moving forward we see great potential in our growing BioPharma pipeline. We look forward to continue building momentum and establishing Applied BioPharma as a leader in the development and commercialization of innovative therapeutics that target the endocannabinoid system,” added Dr. Urbanski.

To date, the Applied BioPharma division has developed partnerships with leading academic and research institutions and has exclusively licensed patented, synthetically derived small molecule candidates which target the endocannabinoid (ECS) G-protein coupled receptors (GPCRs) e.g., the cannabinoid receptor 1 and cannabinoid receptor 2, for the treatment of metabolic diseases (type 2 diabetes, obesity, fatty liver disease) and inflammation (pulmonary inflammation, optic nerve inflammation following traumatic brain injury and ischemic/reperfusion injury such as acute kidney injury post-transplant and acute myocardial infarction (heart attack).

The Company’s growing pipeline is comprised of selective CB1 and CB2 agonist, inverse agonist and antagonists utilizing multiple scaffolds and state-of-the-art medicinal chemistry across several academic centers and institutions. Applied expects to advance the first of its preclinical programs into open INDs throughout 2020 and its lead clinical program into a Phase 1 study in early to mid-2020.

The Company is actively advancing and seeking additional in-license opportunities with the goal of developing an industry-leading pipeline of endocannabinoid system-targeted drug candidates that address significant unmet needs across a wide range of therapeutic areas.

About Applied BioSciences Corp.

Applied BioSciences is a vertically integrated company focused on the development and commercialization of novel, science-driven, synthetic cannabinoid therapeutics / biopharmaceuticals that target the endocannabinoid system to treat a wide-range of diseases across multiple therapeutic areas. We also deliver high-quality consumer and OTC THC-free CBD products that promote overall health and wellbeing as well as state-of-the-art testing and analytics capabilities to our customers. For more information, visit appliedbiocorp.com and connect with the Company on Twitter, Facebook and LinkedIn.

Tags: , , , , , , , , , , ,
Posted in All Recent Posts, Applied BioSciences | Comments Off on Applied BioSciences $APPB: Announces Strategic Shift to Fully Focus on BioPharma Division $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Applied BioSciences $APPB – WHO Report Finds No Public Health Risks Or Abuse Potential For CBD $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 3:57 PM on Wednesday, November 27th, 2019

SPONSOR: Applied Biosciences Corp. is a vertically integrated company focused on the development of science-driven cannabinoid therapeutics and biopharmaceuticals, as well as state-of-the-art testing and analytics. As a leading company in the CBD, Pet and Health and Wellness space, the company is currently shipping to the majority of US states as well as to 5 International countries. Click Here for More Info

A World Health Organization (WHO) report has found no adverse health outcomes but rather several medical applications for cannabidiol, a.k.a. CBD, despite U.S. federal policy on this cannabinoid chemical.

According to a preliminary WHO report published last month, naturally occurring CBD is safe and well tolerated in humans (and animals), and is not associated with any negative public health effects [PDF].

Experts further stated that CBD, a non-psychoactive chemical found in cannabis, does not induce physical dependence and is “not associated with abuse potential.” The WHO also wrote that, unlike THC, people aren’t getting high off of CBD, either.

“To date, there is no evidence of recreational use of CBD or any public health related problems associated with the use of pure CBD,” they wrote. In fact, evidence suggests that CBD mitigates the effects of THC (whether joyous or panicky), according to this and other reports.

The authors pointed out that research has officially confirmed some positive effects of the chemical, however.

The WHO team determined that CBD has “been demonstrated as an effective treatment for epilepsy” in adults, children, and even animals, and that there’s “preliminary evidence” that CBD could be useful in treating  Alzheimer’s disease, cancer, psychosis, Parkinson’s disease, and other serious conditions.

In acknowledgement of these kinds of discoveries in recent years, the report continued, “Several countries have modified their national controls to accommodate CBD as a medicinal product.” 

But the U.S., the report noted, isn’t one of them. As a cannabis component, CBD remains classified as a Schedule I controlled substance, meaning it has a “high potential for abuse” in the federal government’s view. Nevertheless, the “unsanctioned medical use” of CBD is fairly common, experts found.

For many CBD users in the U.S., the substance’s mostly unsanctioned and illegal state creates problems, especially as a wave of online (mostly hemp) and store-bought CBD oils and extracts have allowed patients to take the treatment process–and the risks involved in buying unregulated medicine–into their own hands and homes.

While CBD itself is safe and found to be helpful for many users, industry experts have warned that not all cannabis extracts are created equally, purely, or with the same methods of extraction.

And while reports of negative reactions to pure CBD are very few and far between, researchers are able to say that the cannabinoid wouldn’t be to blame alone. “Reported adverse effects may be as a result of drug-drug interactions between CBD and patients’ existing medications,” they noted.

As the cannabis reform nonprofit NORML reported, the WHO is currently considering changing CBD’s place in its own drug scheduling code. In September, NORML submitted written testimony to the U.S. Food and Drug Administration (FDA) opposing the enactment of in

The FDA, which has repeatedly declined to update its position on cannabis products despite a large and ever-growing body of evidence on the subject, is one of a number of agencies that will be advising the WHO in its final review of CBD.

Perhaps this time around the FDA will listen, and learn something.

The report was presented by the WHO’s Expert Committee on Drug Dependence, and drafted under the responsibility of the WHO Secretariat, Department of Essential Medicines and Health Products, Teams of Innovation, Access and Use and Policy, Governance and Knowledge.

https://www.forbes.com/sites/janetwburns/2018/03/18/who-report-finds-no-public-health-risks-abuse-potential-for-cbd/#52c681102347

Tags: , , , , , , , , , , ,
Posted in All Recent Posts, Applied BioSciences | Comments Off on Applied BioSciences $APPB – WHO Report Finds No Public Health Risks Or Abuse Potential For CBD $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Applied BioSciences $APPB – Reports Second Quarter Fiscal Year 2020 Financial Results and Outlines Corporate Strategy $CGRW $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca

Posted by AGORACOM at 8:45 AM on Friday, November 15th, 2019
  • Successfully building BioPharma pipeline in high-value indications
  • Company plans to advance IND-cleared program into a Phase 1 study in a metabolic disease indication in early 2020
  • Strategic corporate shift to fully focus on BioPharma Division unlocks opportunities for non-dilutive capital to fund pipeline

Applied BioSciences Corp. (OTCQB:APPB) (“Applied” or the “Company”), today announced its financial results for the second quarter Fiscal Year 2020 ended September 30, 2019. The Company also provided an update on its corporate and clinical progress.

“We continue to push forward on all fronts as we work to establish Applied as a leader in the development and commercialization of novel, science-driven, synthetic endocannabinoid therapeutics / biopharmaceuticals and impact areas of significant unmet need,” commented Dr. Raymond Urbanski, Chief Executive Officer of Applied. “Over the course of the past quarter, we have made notable strides on the corporate and clinical front and remain diligent in working to drive value for all stakeholders.”

“We continued to build out our BioPharma division and have established a Scientific Advisory Board of leading experts in the endocannabinoid space. We were pleased to have welcomed our inaugural members Judith Korner, M.D. and Patricia Reggio, Ph.D., who will play an integral role as we look to optimize our therapeutic pipeline and look to make additional appointments in the near term to help drive this business unit forward. Additionally, we have continued to execute on our robust business development initiatives and remain in late-stage discussions to in-license our product candidates that we believe have the potential to address a number of areas with significant unmet need. In tandem, we continue to remain opportunistic in accessing the necessary non-dilutive funding and capital through strategic investments from which we believe will provide us with the foundation and momentum to move forward.”

Applied BioPharma: developing science-driven synthetic cannabinoid therapeutics that satisfy unmet medical needs and continue to drive innovation in the endocannabinoid space.

The Applied BioPharma division is focused on the development and commercialization of novel therapeutics that target the endocannabinoid system (ECS).

Applied Biopharma has to date developed partnerships with leading academic and research institutions and has exclusively licensed patented, synthetically derived small molecule candidates which target the ECS G-protein coupled receptors (GPCRs) e.g., the cannabinoid receptor 1 and cannabinoid receptor 2, for the treatment of metabolic diseases (type 2 diabetes, obesity, fatty liver disease) and inflammation (pulmonary inflammation, optic nerve inflammation following traumatic brain injury and ischemic/reperfusion injury such as acute kidney injury post-transplant and acute myocardial infarction (heart attack).

The Company’s growing pipeline is comprised of selective CB1 and CB2 agonist, inverse agonist and antagonists utilizing multiple scaffolds and state-of-the-art medicinal chemistry across several academic centers and institutions.

  • Applied expects to advance the first of its preclinical programs into open INDs in 2020.
    • ABP-1902, its lead CB2 agonist, intended for mitigating the deleterious effects of ischemic-reperfusion injury.
    • ABP-1901, its lead CB2 inverse agonist, which has demonstrated effectiveness in limiting or reversing damage due to neuroinflammation.
  • Applied expects to advance the first of its clinical programs into a Phase 1 study in early to mid-2020.

The Company is actively advancing and seeking additional in-license opportunities with the goal of developing an industry-leading pipeline of endocannabinoid system-targeted drug candidates that address significant unmet needs across a wide range of therapeutic areas.

Applied Products: portfolio of consumer, animal health, women’s health and sports medicine of hemp-derived, THC-free, pharmaceutical grade CBD isolates and distribution products, all of which ship to the majority of U.S., as well as to multiple non-U.S. countries.

The Applied Products business unit is focused on maximizing top-line revenue through selective investments in product lines and marketing campaigns (increase share-of-voice), continually reevaluating the endocannabinoid Health & Wellness environment for opportunities and developing and implementing a nutraceutical strategy.

Applied Products has seen a modest year-over-year increase in top line revenue. At this time the Board, with the understanding that to be successful in the lucrative yet dynamic and very competitive consumer CBD space would require significant resource and capital allocations, is evaluating various strategic options for this business unit.

Trace Analytics, Inc: Applied’s majority owned subsidiary scalable analytics cannabis/cannabinoid laboratory poised to meet the demands for mandated regulatory cannabis/cannabinoid testing.

In July 2019, Trace Analytics was contracted for services with the Washington State Department of Agriculture (WSDA). This contract includes testing Industrial Hemp samples and include percentage testing for post-decarboxylation delta 9-tetrahydrocannabidiol (THC) and delta 9-tetrahydocannabinolic acid (THC-A) to ensure the percentages of certain cannabinoids are below Federal limits.

Applied is currently in late-stage discussions for a strategic transaction, expected to close by year end.

Upcoming Milestones Expected to Drive Value

  • Finalize the in-licensing of product candidates to build pipeline for the Applied BioPharma division.
  • Closing on the sale of Trace Analytics leading to the infusion of non-dilutive capital into the company.
  • Finalize and execute on the strategic options for Applied Products.
  • Successfully execute overall strategy of the Company and business development efforts.
  • Engage with key stakeholders in the investment community and execute on the robust effort to raise awareness of the Company.
  • Uplist to a National Exchange.

Summary of Financial Results for Second Quarter FY2020 Ended September 30, 2019

For the quarter ended September 30, 2019, the Company reported net loss of approximately $777,746 or net loss per diluted share of $0.06, compared to a net loss of approximately $110,423 or a net loss per diluted share of $0.01, for the quarter ended September 30, 2018.

The Company reported revenues from Applied BioSciences’ CBD product lines was $169,654 and $59,400 during the six months ended September 30, 2019 and 2018, respectively. The increase reflects higher sales across all of the Company’s CBD brand product lines, most notably in its topical products, combined with expansion into sales of bulk hemp seed and raw CBD. Service revenue resulting from the Company’s lab testing is attributed solely to the acquisition of Trace Analytics in January 2019, and totaled $286,077 for the six months ended September 30, 2019.

General and administrative expenses increased $519,140 to $707,192 for the three months ended September 30, 2019 as compared to $188,052 for the three months ended September 30, 2018. The increase was mainly attributable to the acquisition of Trace Analytics and addition of our Applied BioPharma subsidiary, with general and administrative expenses for the remainder of the Company.

The Company ended the quarter with $73,412 in cash and cash equivalents. The Company is actively evaluating opportunities to fund continued growth in its products and services revenue along with planned business development activities for Applied BioPharma and anticipates closing a financing by the end of first quarter Fiscal Year 2020.

About Applied BioSciences Corp.

Applied BioSciences is a vertically integrated company focused on the development and commercialization of novel, science-driven, synthetic cannabinoid therapeutics / biopharmaceuticals that target the endocannabinoid system to treat a wide-range of diseases across multiple therapeutic areas. We also deliver high-quality consumer and OTC THC-free CBD products that promote overall health and wellbeing as well as state-of-the-art testing and analytics capabilities to our customers. For more information, visit appliedbiocorp.com and connect with the Company on Twitter, Facebook and LinkedIn.

Tags: , , , , , , , , , , ,
Posted in All Recent Posts, Applied BioSciences | Comments Off on Applied BioSciences $APPB – Reports Second Quarter Fiscal Year 2020 Financial Results and Outlines Corporate Strategy $CGRW $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca

« Older Entries